Effect of levosimendan on renal function in background of left ventricular dysfunction: a meta-analysis of randomized trials

References

• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 Update: a report from the american heart association. Circulation. 2017;135(10):e146–e603.
   PubMed Web of Science ®Google Scholar
• Algarni KD, Maganti M, Yau TM. Predictors of low cardiac output syndrome after isolated coronary artery bypass surgery: trends over 20 years. Ann Thorac Surg. 2011;92(5):1678–1684.
   PubMed Web of Science ®Google Scholar
• Bello NA, Claggett B, Desai AS, et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail. 2014;7(4):590–595.
   PubMed Web of Science ®Google Scholar
• Schumann J, Henrich EC, Strobl H, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2018;1(1):CD009669.
   PubMedGoogle Scholar
• Farmakis D, Alvarez J, Gal TB, et al. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol. 2016;222:303–312.
   PubMed Web of Science ®Google Scholar
• Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196–202.
   PubMed Web of Science ®Google Scholar
• Fedele F, Bruno N, Brasolin B, et al. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014;16(3):281–288.
   PubMed Web of Science ®Google Scholar
• Kapoor JR, Kapoor R, Ju C, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail. 2016;4(6):464–472.
   PubMed Web of Science ®Google Scholar
• Lala RI, Lungeanu D, Puschita M, et al. Acute kidney injury: a clinical issue in hospitalized patients with heart failure with mid-range ejection fraction. Pol Arch Intern Med. 2018;128(12):746–754.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2019;10(ED000142). DOI:https://doi.org/10.1002/14651858.ED14000142
   Google Scholar
• Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926.
   PubMed Web of Science ®Google Scholar
• Sun X, Briel M, Walter SD, et al. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340(mar30 3):c117.
   PubMedGoogle Scholar
• Knezevic I, Poglajen G, Hrovat E, et al. The effects of levosimendan on renal function early after heart transplantation: results from a pilot randomized trial. Clin Transplant. 2014;28(10):1105–1111.
   PubMed Web of Science ®Google Scholar
• Zhou C, Gong J, Chen D, et al. Levosimendan for prevention of acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2016;67(3):408–416.
   PubMed Web of Science ®Google Scholar
• Bove T, Matteazzi A, Belletti A, et al. Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Heart Lung Vessel. 2015;7(1):35–46.
   PubMed Web of Science ®Google Scholar
• Cui D, Liao Y, Li G, et al. Levosimendan can improve the level of B-type natriuretic peptide and the left ventricular ejection fraction of patients with advanced heart failure: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2020;28(10):020–00416.
   Google Scholar
• Gong B, Li Z, Yat Wong PC. Levosimendan treatment for heart failure: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2015;29(6):1415–1425.
   PubMed Web of Science ®Google Scholar
• Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;38(4):955–962.
   PubMed Web of Science ®Google Scholar
• Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422–430.
   PubMed Web of Science ®Google Scholar
• Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113(5):671–678.
   PubMed Web of Science ®Google Scholar
• Zhou X, Hu C, Xu Z, et al. Effect of levosimendan on clinical outcomes in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Interact Cardiovasc Thorac Surg. 2018;26(6):1016–1026.
   PubMed Web of Science ®Google Scholar
• Chen QH, Zheng RQ, Lin H, et al. Effect of levosimendan on prognosis in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Crit Care. 2017;21(1):253.
   PubMed Web of Science ®Google Scholar
• Xing Z, Tang L, Chen P, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery: a meta-analysis and trial sequential analysis of randomized trials. Sci Rep. 2018;8(1):7775.
   PubMed Web of Science ®Google Scholar
• Thiele RH, Isbell JM, Rosner MH. AKI associated with cardiac surgery. Clin J Am Soc Nephrol. 2015;10(3):500–514.
   PubMed Web of Science ®Google Scholar
• Massoth C, Zarbock A, Meersch M. Acute kidney injury in cardiac surgery. Crit Care Clin. 2021;37(2):267–278.
   PubMed Web of Science ®Google Scholar
• Grossini E, Molinari C, Pollesello P, et al. Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012;342(2):376–388.
   PubMed Web of Science ®Google Scholar
• Herrera GM, Resta TC, Candelaria JJ, et al. Maintained vasodilatory response to cromakalim after inhibition of nitric oxide synthesis. J Cardiovasc Pharmacol. 1998;31(6):921–929.
   PubMed Web of Science ®Google Scholar
• Qiu J, Jia L, Hao Y, et al. Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis. Life Sci. 2017;184:30–36.
   PubMed Web of Science ®Google Scholar
• Abdelrahman AM, Al Salam S, Al Suleimani Y, et al. Effect of levosimendan, an inodilator, on streptozotocin-induced diabetic nephropathy in rats. Eur J Pharmacol. 2020;873:172960.
   PubMed Web of Science ®Google Scholar
• Uhlig K, Efremov L, Tongers J, et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev. 2020;11(CD009669). DOI:https://doi.org/10.1002/14651858.CD009669.pub4
   Google Scholar
• Triposkiadis F, Parissis JT, Starling RC, Triposkiadis F, Parissis JT, Starling RC, Skoularigis J, Louridas G. Current drugs and medical treatment algorithms in the management of acute decompensated heart failure. Expert Opin Investig Drugs. 2009;18(6):695–707. .
   PubMed Web of Science ®Google Scholar
• Lannemyr L, Bragadottir G, Redfors B, et al. Effects of milrinone on renal perfusion, filtration and oxygenation in patients with acute heart failure and low cardiac output early after cardiac surgery. J Crit Care. 2020;57:225–230.
   PubMed Web of Science ®Google Scholar
• Westman L, Järnberg PO. Effects of dobutamine on haemodynamics and renal function in patients after major vascular surgery. Acta Anaesthesiol Scand. 1987;31(3):253–257.
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail. 2009;11(3):304–311.
   PubMed Web of Science ®Google Scholar
• Puttonen J, Kantele S, Kivikko M, et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet. 2007;46(3):235–246.
   PubMed Web of Science ®Google Scholar
• Chan CC, Lee KT, Ho WJ, et al. Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study. Ann Intensive Care. 2021;11(1):27.
   PubMed Web of Science ®Google Scholar